In another work aiming to improve the proliferation, homing, and persistence of anti-tumor ACT cells, NKTR-214, a novel IL2Rβγ-biased cytokine, was designed to function as an alternative to conventional IL-2 [40] (Figure 3B). The gene discussed is IL2; the disease is neoplasm.